Cilostazol is indicated for the reduction of symptoms of intermittent claudication, as indicated by an increased walking distance.
Phosphodiesterase Inhibitor; Vasodilator
Cilostazol is a preparation of Cilostazol which is a quinolinone derivative. The mechanism of action is to specifically inhibit cellular phosphodiesterase III (PDE III) and suppress cAMP degradation with a resultant increase in cAMP in platelets and blood vessels, leading to inhibition of platelet aggregation and vasodilation.
The recommended dosage of Cilosta is 100 mg bid, taken at least half an hour before or two hours after breakfast & dinner. A dose of 50 mg bid should be considered during coadministration of Ketoconazole, Itraconazole, Erythromycin, & Diltiazem.
Pharmacokinetic studies have demonstrated that Omeprazole and Erythromycin significantly increased the systemic exposure of Cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of Cilostazol among patients concurrently treated with Diltiazem.
Cilostazol is contraindicated in patients with congestive heart failure of any severity. Cilostazol is also contraindicated in patients with known or suspected hypersensitivity to any of its components. There is no information with respect to the efficacy or safety of the concurrent use of Cilostazol & Clopidogrel.
The most common side effects are headache, diarrhoea, vomiting, leg cramps, rash etc. The less frequent side effects are anorexia & oedema.
Pregnancy: There are no adequate & well controlled studies in pregnant women. Lactation: Transfer of Cilostazol into milk has been reported in experimental animals. Because of the potential risk to nursing infants, a decision should be made to discontinue nursing or to discontinue Cilostazol.
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
.png&w=384&q=75)